Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer - Phase II study of XELIRI and bevacizumab as second-line therapy

Kitasato university school of medicine0 个研究点目标入组 38 人开始时间: 2012年8月11日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Metastases to the CNS 2. Complication of cerebrovascular disease or symptoms within 1 years 3. Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week 4. Patient with untreated traumatic bone fracture 5. History of gastrointestinal perforation within 1 year 6. uncontrolled peptic ulcer 7. Diathesis of bleeding (history of hemoptysis,including cavitation and/or necrosis in lung metastasis confirmed by imaging),coagulopathy. 8. Administering antithrombotic drug within 10 days before enrollment 9. anti-platelets therapy 10. History of thrombosis or cerebrovascular disorder 12. Serious heart disease 11. Uncontrolled high blood pressure 12. Massive pleural effusion or ascites that required drainage 13.Multiple primary cancer which heals within five years 14. Patient who have peripheral nerve disorder 15.Interstitial pneumonitis 16. Uncontrolled diarrhea 17.Severe infection disease 18. The patient who has the past of the organ transplantation to need an immunosuppressive drug 19.Pregnant or lactating women or women of childbearing potential 20.History of severe allergy with Bevacizumab or Capecitabine 21. History of adverse events related to DPD loss 22. Other conditions not suitable for this study

发起方

Kitasato university school of medicine